gene_symbol
ERBB2
hgnc_id
HGNC:3430
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
Trastuzumab binds HER2 on tumor cells and its Fc engages immune effectors (e.g., NK cells) via Fcγ receptors to trigger ADCC; it can also activate complement (CDC) and inhibit HER2 signaling, promoting apoptosis.
enzyme_product
On
epitope
On
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Binds extracellular domain (primarily domain IV) to block dimerization/signaling and mediate ADCC
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06178445
disease_id_num_tar_ref
974
drug_id_num_tar_ref
2669